John Curran (Dublin Mid West, Fianna Fail) | Oireachtas source

At the end of February, the HSE decided not to reimburse Spinraza at its then price. It said that the company involved had 28 days to make further observations or submissions. Has there been an engagement between the company and the HSE during that period? If so, what is the current state of play? If no progress is being made, what steps can the Government take to review the Health (Pricing and Supply of Medical Goods) Act 2013? This drug is available to children in every other European country. We cannot make it available because we are caught up in our own red tape. If the process is not working, can we look at reviewing the 2013 Act?

See this speech in context